May 22 (Reuters) - Sinovac Biotech Ltd:
* SINOVAC SECURES $15 MILLION IN FUNDING TO ACCELERATE COVID-19 VACCINE DEVELOPMENT
* SINOVAC BIOTECH LTD - ADVANTECH CAPITAL AND VIVO CAPITAL HAVE INVESTED $15 MILLION IN SINOVAC RESEARCH AND DEVELOPMENT
* SINOVAC BIOTECH LTD - TWO INVESTORS EACH LOANED $7.5 MILLION IN FORM OF CONVERTIBLE LOAN THAT BEARS INTEREST
* SINOVAC BIOTECH - RECEIVED APPROVAL FROM GOVERNMENTAL AUTHORITIES TO CONDUCT BOTH PHASE I & PHASE II HUMAN CLINICAL TRIALS FOR CORONAVAC IN CHINA
* SINOVAC BIOTECH - PHASE I CLINICAL TRIAL, WHICH EVALUATES SAFETY, TOLERANCE, PRELIMINARY IMMUNOGENICITY OF CORONAVAC, COMMENCED IN APRIL Source text for Eikon: Further company coverage:
Our Standards: The Thomson Reuters Trust Principles.